AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00513981
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05859919
Drug: The drug Rutan 0.1.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose.
Trial: NCT02645240
Drug: Heparin injection
RxNorm normalized name: heparin Injection
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
Trial: NCT02042989
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase.
Trial: NCT02108548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02108548
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02364830
Drug: Colpermin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colpermin® Capsule/Day for 4 Weeks
Trial: NCT03751098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyewash administered with the Optejet microdose dispenser
Trial: NCT03950830
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 400mg daily, continuously
Trial: NCT00566241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03906617
Drug: Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
Trial: NCT04382781
Drug: NO-Immunosuppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not receiving immunosuppressive drugs
Trial: NCT04382781
Drug: Immunosuppressive
RxNorm normalized name: Immunosuppressive acidic protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving immunosuppressive drugs (overall, and specific drugs)
Trial: NCT04382781
Drug: Immunoglubulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving immunoglubulins
Trial: NCT01867125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Trial: NCT00223041
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A receives fluvastatin Arm b receives no fluvastatin
Trial: NCT02137213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be added to oral methadone preparations as placebo.
Trial: NCT00529503
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
Trial: NCT02531308
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferes with DNA replication
Trial: NCT02531308
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anthracycline antitumor antibiotic
Trial: NCT04177095
Drug: Immunosuppression reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
Trial: NCT02211209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01532856
Drug: Thalidomide, Cyclophosphamide, Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
Trial: NCT04009525
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide（50 mg/kg/day,4 days）
Trial: NCT04009525
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate
Trial: NCT01252095
Drug: PG545
RxNorm normalized name: Heparan Sulfate Mimetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
Trial: NCT04752852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
Trial: NCT01088763
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01753310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 2mL
Trial: NCT03447925
Drug: Medicinal Plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicinal Plant Extract with vaseline cream
Trial: NCT03193853
Drug: Tak-228 & Tak-117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.
Trial: NCT01537926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill manufactured to minic NAC 600mg capsule
Trial: NCT00290953
Drug: SR48692
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00669097
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01636271
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00941486
Drug: FST-100 Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.
Trial: NCT00941486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A regimen of 2 drops 4 times a day while awake for 5 days.
Trial: NCT00580151
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose every 6 hours
Trial: NCT01862926
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03139474
Drug: Gonadotropin-Releasing Hormone Analogue
RxNorm normalized name: Gonadotropin releasing hormone analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
Trial: NCT03139474
Drug: Gonadotropin releasing hormone antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach \> 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
Trial: NCT00880412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
Trial: NCT03113812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00184886
Drug: Methotrexate 15 mg/week for 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00615550
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
Trial: NCT01731119
Drug: Latuda©
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
Trial: NCT01205269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation, single dose
Trial: NCT01205269
Drug: AZD8683, 200 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry powder for inhalation, single dose
Trial: NCT02192463
Drug: NVP ER 300 mg (KCR 30%) Slow Release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192463
Drug: NVP ER 300 mg (KCR 40%) Slow Release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192463
Drug: NVP ER 300 mg (ECR 20%) Fast Release
RxNorm normalized name: phentermine hydrochloride Extended Release Oral Tablet [Pro-Fast]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192463
Drug: NVP ER 400 mg (KCR 30%) Slow Release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192463
Drug: NVP ER 400 mg (KCR 40%) Slow Release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02192463
Drug: NVP ER 400 mg (ECR 20%) Fast Release
RxNorm normalized name: phentermine hydrochloride Extended Release Oral Tablet [Pro-Fast]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01991743
Drug: Group 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of bupivacaine 2.5 mg.
Trial: NCT01991743
Drug: Group 5
RxNorm normalized name: Chlamydophila psittaci biogroup 5 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 5 mg bupivacaine
Trial: NCT00987337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT03830333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline by IV infusion every 8 hours for 4 to 14 days.
Trial: NCT01768377
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 2 microgram/Kg BW IV
Trial: NCT01129427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: matching tablet~Route of administration: oral
Trial: NCT04432766
Drug: BAT2020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
Trial: NCT01047566
Drug: Beta blocker or calcium antagonist or digoxin
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increase of beta blocker or calcium antagonist or digoxin
Trial: NCT02276248
Drug: GDP chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
Trial: NCT00802048
Drug: Local anesthetic (Ropivacaine)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic infusion
Trial: NCT04231617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03379727
Drug: anthracycline ((daunorubicin or idarubicin): Induction Phase only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
Trial: NCT02644668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granules for oral suspension (placebo)
Trial: NCT03126968
Drug: Topical epinephrine
RxNorm normalized name: epinephrine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic topical epinephrine
Trial: NCT03126968
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo (normal saline)
Trial: NCT02547220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 7 doses of matched placebo over 13 days of treatment.
Trial: NCT01188031
Drug: NIRAVAM TM 2 mg orally disintegrating tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
Trial: NCT04033861
Drug: rhBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
Trial: NCT00655408
Drug: elemental iron
RxNorm normalized name: Elemental Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation.
Trial: NCT01730053
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin over-encapsulated tablets orally.
Trial: NCT01730053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for alirocumab and ezetimibe.
Trial: NCT01663961
Drug: YM178 OCAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00382200
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03192488
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin placebo
Trial: NCT00209261
Drug: MINIRIN Oral Lyophilisate
RxNorm normalized name: Miniprin Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005791
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00360685
Drug: Tac+MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
Trial: NCT01660750
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO on days 1, 8, and 15 every 28 days
Trial: NCT00901550
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
Trial: NCT00118339
Drug: chemoprotection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02512302
Drug: Seebri® Breezhaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Trial: NCT01100086
Drug: Reformulated OXY (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 10-mg tablet x 1 dose taken without food
Trial: NCT01100086
Drug: Original OxyContin® (OXY) (oxycodone HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
Trial: NCT00683618
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule/Tablet, oral, qd, 6 or 12 weeks
Trial: NCT00730483
Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02844933
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral solution
Trial: NCT02984865
Drug: Sulfentanyl
RxNorm normalized name: Sufentanyl
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02984865
Drug: flubiprofen axetil
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02004366
Drug: Basal Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
Trial: NCT01479465
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours
Trial: NCT01479465
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours
Trial: NCT01822639
Drug: GSK2944404 FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
Trial: NCT02225639
Drug: PRC-063 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25 mg capsule - active
Trial: NCT02225639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsule
Trial: NCT02225639
Drug: PRC-063 35 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 35 mg capsule - active
Trial: NCT02225639
Drug: PRC-063 45 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 45 mg capsule - active
Trial: NCT02225639
Drug: PRC-063 55 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 55 mg capsule - active
Trial: NCT02225639
Drug: PRC-063 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 100 mg capsule - active
Trial: NCT02826486
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
Trial: NCT01760304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated.
Trial: NCT03168711
Drug: Inosine
RxNorm normalized name: Inosine
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
Trial: NCT03168711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
Trial: NCT02861105
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
Trial: NCT03136237
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 of Cohort 2
Trial: NCT02110303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet (identical to ticagrelor), twice daily, 12 month duration
Trial: NCT00314340
Drug: hydrocodone plus acetaminophen
RxNorm normalized name: acetaminophen / hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00314340
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02139098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02894645
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02894645
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal/ Intravenous/ Oral
Trial: NCT02894645
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous